CoChat

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma

Open access

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index; 10 of the 14 sources its claims cite were checked for support.

Abstract

Background Immune checkpoint inhibitors (ICIs) are promising agents for unresectable hepatocellular carcinoma (uHCC), but lack effective biomarker to predict outcomes. The gut microbiome can modulate tumor response to immunotherapy, but its effect on HCC remains unclear. Methods From May 2018 to February 2020, patients receiving ICI treatment for uHCC were prospectively enrolled; their fecal samples were collected before treatment. The fecal microbiota and metabolites were analyzed from 20 patients with radiology-proven objective responses (OR) and 21 randomly selected patients with progressive disease (PD). After March 2020, 33 consecutive Child-Pugh-A patients were recruited as a validation cohort. Additionally, feces from 17 healthy volunteers were collected for comparison of background microbes. Results A significant dissimilarity was observed in fecal bacteria between patients with OR and patients with PD before immunotherapy. Prevotella 9 was enriched in patients with PD, whereas Lachnoclostridium, Lachnospiraceae, and Veillonella were predominant in patients with OR. Ursodeoxycholic acid and ursocholic acid were significantly enriched in the feces of patients with OR and strongly correlated with the abundance of Lachnoclostridium . The coexistence of Lachnoclostridium enrichment and Prevotella 9 depletion significantly predicted better overall survival (OS). In the validation cohort, better progression-free survival (PFS) and OS were noted in patients who had a preferable microbial signature in comparison with counter-group (PFS: 8.8 months vs 1.8 months; OS: not reached vs 6.5 months, both p<0.001). Conclusions Fecal microbiota and bile acids were associated with outcomes of immunotherapy for uHCC. These findings highlight the potential role of gut microbiota and metabolites as biomarkers to predict outcomes of ICI-treated HCC.

Overview

CoChat Summary

TL;DR

In a prospective biomarker study of immune checkpoint inhibitor (ICI)-treated unresectable hepatocellular carcinoma (uHCC), baseline fecal microbiota and bile acids differed between responders and progressors, and a microbial signature of Lachnoclostridium enrichment plus Prevotella 9 depletion predicted better survival. A validation cohort confirmed better progression-free and overall survival with this favorable signature.

Key findings

  • Fecal bacteria differed significantly between objective responders (OR) and progressive disease (PD) before immunotherapy: Prevotella 9 was enriched in PD, whereas Lachnoclostridium, Lachnospiraceae, and Veillonella predominated in OR.
  • Ursodeoxycholic acid (UDCA) and ursocholic acid (UCA) were significantly enriched in OR feces and strongly correlated with Lachnoclostridium abundance.
  • Coexistence of Lachnoclostridium enrichment and Prevotella 9 depletion significantly predicted better overall survival (OS); in the validation cohort, this good microbial signature was associated with PFS of 8.8 months vs 1.8 months and OS not reached vs 6.5 months (both p<0.001).
  • In the validation cohort, the best ORR was 52.6% and DCR was 94.7% in patients with the good microbial signature.

Methods

  • Prospective enrollment from May 2018 to February 2020 of 94 ICI treatment-naïve patients with uHCC at Taipei Veterans General Hospital; fecal samples were collected before treatment. Discovery analysis compared 20 patients with radiology-proven OR (3 complete responses, 17 partial responses) and 21 randomly selected patients with PD; after March 2020, 33 consecutive Child-Pugh-A patients formed a validation cohort, and feces from 17 healthy volunteers were used for background comparison.
  • Fecal microbiota was analyzed by 16S rRNA V3-V4 sequencing with QIIME/SILVA, PCoA of Bray-Curtis dissimilarity, PERMANOVA, LEfSe, and Spearman correlation; fecal bile acids were measured by UHPLC-MS/MS (39 BAs) and short-chain fatty acids by HPLC.
  • Tumor response was assessed by RECIST V.1.1; OS and PFS were estimated by Kaplan-Meier and compared by log-rank test, with Cox proportional-hazard models for prognostic factors; p<0.05 was considered significant.

Limitations

  • The paper states it could not determine causality between differential bacteria or metabolites and tumor outcomes; mechanistic associations between Lachnoclostridium and secondary bile acids need in vitro investigation; dynamic microbiota/metabolite sampling was not performed; findings may not apply to atezolizumab plus bevacizumab; not all patients had paired PBMC or biopsy samples; and most patients had viral-related HCC, so generalizability to non-viral HCC requires further study.
  • Evident from the text: the discovery cohort was small (20 OR and 21 PD), and the validation cohort included 33 patients, limiting statistical power and broader generalizability.
  • Evident from the text: more OR patients received ICI plus tyrosine kinase inhibitor combination therapy than PD patients (60.0% vs 23.8%, p=0.019), a potential baseline imbalance, although the authors report combination treatment was not a significant survival factor in their cohort.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/jitc-2022-004779

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The diversities and predominant fecal bacteria in patients received immune checkpoint inhibitor (ICI) treatment for unresectable hepatocellular carcinoma (HCC) and healthy controls. (A) Principle coordinates analysis of fecal microbiota by Bray-Curtis dissimilarity metrics. (B) Histograms and (C) cladogram of linear discriminant analysis (LDA) scores computed for differentially abundant taxa in the fecal microbiome. The length of each bar indicates the effect size associated with a taxon, which is significantly different when comparing to other groups. OR, objective response; PD, progressive disease.
Figure 1 The diversities and predominant fecal bacteria in patients received immune checkpoint inhibitor (ICI) treatment for unresectable hepatocellular carcinoma (HCC) and healthy controls. (A) Principle coordinates analysis of fecal microbiota by Bray-Curtis dissimilarity metrics. (B) Histograms and (C) cladogram of linear discriminant analysis (LDA) scores computed for differentially abundant taxa in the fecal microbiome. The length of each bar indicates the effect size associated with a taxon, which is significantly different when comparing to other groups. OR, objective response; PD, progressive disease.CC BY-NC · PubMed Central
Figure 2 The concentration of secondary bile acids in the feces of patients received immune checkpoint inhibitor (ICI) treatment for unresectable hepatocellular carcinoma (HCC) and healthy controls. DCA, deoxycholic acid; G, glycine conjugated species; LCA, lithocholic acid; MDCA, murideoxycholic acid (murocholic acid); nM, nanomolar; T, taurine-conjugated species; UCA, ursocholic acid; UDCA, ursodeoxycholic acid.
Figure 2 The concentration of secondary bile acids in the feces of patients received immune checkpoint inhibitor (ICI) treatment for unresectable hepatocellular carcinoma (HCC) and healthy controls. DCA, deoxycholic acid; G, glycine conjugated species; LCA, lithocholic acid; MDCA, murideoxycholic acid (murocholic acid); nM, nanomolar; T, taurine-conjugated species; UCA, ursocholic acid; UDCA, ursodeoxycholic acid.CC BY-NC · PubMed Central
Figure 3 Heatmap of the correlation analysis between the predominant bacterial taxa and fecal bile acids in patients with unresectable hepatocellular carcinoma (HCC). MCA, muricholic acid; MuroCA, murocholic acid (=murideoxycholic acid); THCA, taurohyocholic acid; (T) UDCA, (tauro)ursodeoxycholic acid. The red color indicates positive correlation and the blue color indicates negative correlation. +p<0.05; ++p<0.01.
Figure 3 Heatmap of the correlation analysis between the predominant bacterial taxa and fecal bile acids in patients with unresectable hepatocellular carcinoma (HCC). MCA, muricholic acid; MuroCA, murocholic acid (=murideoxycholic acid); THCA, taurohyocholic acid; (T) UDCA, (tauro)ursodeoxycholic acid. The red color indicates positive correlation and the blue color indicates negative correlation. +p<0.05; ++p<0.01.CC BY-NC · PubMed Central
Figure 4 Overall survivals of patients with unresectable hepatocellular carcinoma (HCC) treated by checkpoint inhibitor (ICI). Overall survival depended on the relative abundance of (A) fecal Prevotella 9; (B) fecal Lachnoclostridium; and (C) signature of combined these two taxa. Good signature: coexistence of depleted Prevotella 9 and enriched Lachnoclostridium. Poor signature: coexistence of enriched Prevotella 9 and depleted Lachnoclostridium. Fair signature: coexistence of depleted both two bacteria or enriched both two bacteria.
Figure 4 Overall survivals of patients with unresectable hepatocellular carcinoma (HCC) treated by checkpoint inhibitor (ICI). Overall survival depended on the relative abundance of (A) fecal Prevotella 9; (B) fecal Lachnoclostridium; and (C) signature of combined these two taxa. Good signature: coexistence of depleted Prevotella 9 and enriched Lachnoclostridium. Poor signature: coexistence of enriched Prevotella 9 and depleted Lachnoclostridium. Fair signature: coexistence of depleted both two bacteria or enriched both two bacteria.CC BY-NC · PubMed Central
Figure 5 Progression-free survival and overall survivals of patients in validation. Progression-free survival and overall survival depended on the relative abundance of (A, D) fecal Prevotella 9; (B, E) fecal Lachnoclostridium; and (C, F) signature of combined these two taxa.
Figure 5 Progression-free survival and overall survivals of patients in validation. Progression-free survival and overall survival depended on the relative abundance of (A, D) fecal Prevotella 9; (B, E) fecal Lachnoclostridium; and (C, F) signature of combined these two taxa.CC BY-NC · PubMed Central

Verification

Claims the paper makes

9 Valid · 0 Not valid · 2 Not checked · 38 Own results and interpretations

29 more claims

Create a free account to see all 49 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 13
  • It may state two separate claims as one. 6

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 52 references

Cited by

See all 217

Metadata

Authors
Lee, P.-C., Wu, C.-J., Hung, Y.-W., Lee, C. J., Chi, C.-T., Lee, I.-C., Yu-Lun, K., Chou, S.-H., Luo, J.-C., Hou, M.-C., & Huang, Y.-H.
Affiliations
  • National Yang Ming Chiao Tung University (TW)
  • Taipei Veterans General Hospital (TW)
  • Biotools Co. Ltd, New Taipei City, Taiwan
Corresponding author
Huang, Yi-Hsiang
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2022-06
Volume
10
Issue
6
Pages
e004779
ISSN
2051-1426 (ISSN-L)
OpenAlex
W4283314687
Cited by
217
References
53
Citations by year
2026: 61 · 2025: 65 · 2024: 45 · 2023: 42 · 2022: 4
FWCI
13.05
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Ministry of Science and Technology of Taiwan (MOST 108-2321-B-010 -017)
  • Taipei Veterans General Hospital (V109C-048, V110C-144)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
gut microbiota, immune checkpoint inhibitors, unresectable hepatocellular carcinoma, fecal metabolites, bile acids, ursodeoxycholic acid, Lachnoclostridium, Prevotella 9, immunotherapy response prediction, prognostic factors, overall survival, progression-free survival
MeSH terms
Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma. https://app.cochat.ai/papers/10.1136/jitc-2022-004779
The paper
Lee, P.-C., Wu, C.-J., Hung, Y.-W., Lee, C. J., Chi, C.-T., Lee, I.-C., Yu-Lun, K., Chou, S.-H., Luo, J.-C., Hou, M.-C., & Huang, Y.-H. (2022). Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-004779

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.